arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Immunovant, Inc.

IMVT Health Care Biotechnology: Biological Products (No Diagnostic Substances)
$29.10
▲ +1.8% Today
as of Oct 22, 16:49 ET
Last 30 days -22.73% Sep 14 → Oct 22
$25.86 $29.03 $32.19 $35.36 $38.53 Sep 14 Sep 22 Sep 29 Oct 07 Oct 14 Oct 22
Open
$28.09
High
$29.12
Low
$27.98
Volume
$1M
Avg Vol
$2M
Mkt Cap
$7.0B
P/E (TTM)
—
Beta
—
52w High
$45.42
52w Low
$18.51
Div Yield
—
Shares Out
$206M

Recent Press Releases & News last 60 days · 19 items

Oct 21 · 11:00 PR GlobeNewswire
Immunovant to Report Financial Results for the Second Fiscal Quarter Ended September 30, 2026, and Provide Business Update on Monday, November 9, 2026
Oct 20 · 14:14 Simply Wall St.
Immunovant (IMVT) Stock Looks Stretched On Book Value Alone
Oct 8 · 17:33 Stocktwits
IMVT, ROIV Stocks Slide As Argenx Sjögren’s Trial Failure Hits Drug Class
▸ Show all 19 press releases & news Free account →

IMVT earnings at a glance

The options market is pricing a move of about ±7.3% after the report, a range of roughly $26.98 to $31.22 from today's $29.10. Over its last 2 reports the stock rose the next day 2 times and fell 0, moving ±20.4% on average; after the most recent report on May 20, 2026 it moved +35.3%. That means options currently expect less movement than IMVT has typically delivered. IMVT beat the consensus EPS estimate in 2 of its last 4 reported quarters. Implied volatility is currently 62%. The share price of $29.10 sits in the middle of its 52-week range.

More Health Care stocks · All stocks · Earnings calendar

Overview

52-week range
$19
$45
39% of range
Avg surprise (last 4)
+0.3%
Avg reaction (last 2)
+20.4%
100% positive
Latest IV / EM
62%
EM ±7.3% · $30 · Oct 16

Earnings trends

EPS — actual vs estimate Actual Estimate
$-0.76$-0.66$-0.56$-0.46$-0.36 Actual $-0.57Actual $-0.45Actual $-0.36Actual $-0.60Actual $-0.74Actual $-0.76Actual $-0.64Est $-0.72Actual $-0.60Est $-0.69Actual $-0.73Est $-0.72Actual $-0.61Actual $-0.73Est $-0.60Actual $-0.75 JunSepDecJunSepDecMar/2025Jun/2025Sep/2025DecMar/2026Jun
Revenue vs Net Income Revenue Net income
$-153M$-144M$-134M$-124M$-115M Sep 24Dec 24Jun 25Sep 25Dec 25Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Tue Jun 30, 2026Jun 2026 $-0.75 — — — — financials
Wed May 20, 2026Mar/2026 $-0.73 $-0.60 -21.7% -14.1% +35.3% earnings
Wed Dec 31, 2025Dec 2025 $-0.61 — — — — financials
Mon Nov 10, 2025Sep/2025 $-0.73 $-0.72 -1.4% — — earnings
Mon Aug 11, 2025Jun/2025 $-0.60 $-0.69 +13.0% — — earnings
Thu May 29, 2025Mar/2025 $-0.64 $-0.72 +11.1% — +5.6% earnings
Tue Dec 31, 2024Dec 2024 $-0.76 — — — — financials
Mon Sep 30, 2024Sep 2024 $-0.74 — — — — financials
Sun Jun 30, 2024Jun 2024 $-0.60 — — — — financials
Sun Dec 31, 2023Dec 2023 $-0.36 — — — — financials
Sat Sep 30, 2023Sep 2023 $-0.45 — — — — financials
Fri Jun 30, 2023Jun 2023 $-0.57 — — — — financials
Sat Dec 31, 2022Dec 2022 $-0.49 — — — — financials

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue————————
Cost of revenue————————
Gross profit————————
Operating income————————
Net income$-153M—$-111M$-127M$-121M—$-111M$-109M
EPS (diluted)$-0.75—$-0.61$-0.73$-0.71—$-0.76$-0.74

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$798M$902M$995M$522M$599M$714M$375M$473M
Inventory————————
Total current assets$851M$949M$1.04B$574M$652M$768M$413M$507M
Total assets$852M$957M$1.05B$583M$661M$776M$421M$516M
Long-term debt————————
Total liabilities$117M$104M$66M$63M$53M$69M$68M$67M
Total equity$735M$853M$986M$520M$609M$707M$353M$449M

Implied volatility — last 90 days

44%61%78%96%113% Jun 07 — IV 73% · EM ±10.0%Jun 08 — IV 81% · EM ±10.6%Jun 09 — IV 62% · EM ±7.8%Jun 10 — IV 69% · EM ±8.2%Jun 11 — IV 79% · EM ±8.7%Jun 12 — IV 60% · EM ±6.1%Jun 15 — IV 80% · EM ±5.8%Jun 19 — IV 49% · EM ±10.8%Jun 22 — IV 65% · EM ±13.5%Jun 23 — IV 64% · EM ±13.2%Jun 24 — IV 64% · EM ±12.8%Jun 25 — IV 65% · EM ±12.8%Jun 26 — IV 62% · EM ±11.8%Jun 29 — IV 65% · EM ±11.5%Jun 30 — IV 49% · EM ±8.4%Jul 01 — IV 45% · EM ±7.5%Jul 02 — IV 50% · EM ±8.1%Jul 03 — IV 52% · EM ±8.1%Jul 06 — IV 52% · EM ±7.3%Jul 07 — IV 51% · EM ±6.8%Jul 08 — IV 47% · EM ±5.8%Jul 09 — IV 71% · EM ±8.4%Jul 13 — IV 97% · EM ±8.1%Jul 15 — IV 45% · EM ±2.6%Jul 20 — IV 80% · EM ±18.9%Jul 21 — IV 83% · EM ±19.3%Jul 22 — IV 74% · EM ±16.8%Jul 23 — IV 69% · EM ±15.5%Jul 24 — IV 72% · EM ±16.0%Jul 27 — IV 79% · EM ±16.5%Jul 28 — IV 72% · EM ±14.7%Jul 29 — IV 85% · EM ±17.0%Jul 30 — IV 79% · EM ±15.4%Jul 31 — IV 79% · EM ±15.1%Aug 03 — IV 85% · EM ±15.1%Aug 04 — IV 63% · EM ±10.8%Aug 05 — IV 76% · EM ±12.7%Aug 06 — IV 72% · EM ±11.6%Aug 07 — IV 62% · EM ±9.8%Aug 10 — IV 62% · EM ±8.6%Aug 11 — IV 64% · EM ±8.4%Aug 12 — IV 81% · EM ±10.1%Aug 13 — IV 64% · EM ±7.5%Aug 14 — IV 60% · EM ±6.6%Aug 17 — IV 85% · EM ±7.1%Aug 18 — IV 102% · EM ±7.4%Aug 19 — IV 68% · EM ±4.0%Aug 24 — IV 76% · EM ±15.8%Aug 25 — IV 69% · EM ±14.1%Aug 26 — IV 69% · EM ±13.8%Aug 27 — IV 66% · EM ±13.0%Aug 28 — IV 68% · EM ±13.0%Aug 31 — IV 74% · EM ±13.1%Sep 01 — IV 73% · EM ±12.5%Sep 02 — IV 83% · EM ±13.9%Sep 03 — IV 65% · EM ±10.5%Sep 04 — IV 69% · EM ±10.8%Sep 07 — IV 78% · EM ±10.8%Sep 08 — IV 87% · EM ±11.4%Sep 09 — IV 98% · EM ±12.3%Sep 10 — IV 74% · EM ±8.7%Sep 11 — IV 90% · EM ±9.9%Sep 14 — IV 92% · EM ±7.7%Sep 15 — IV 113% · EM ±8.2%Sep 21 — IV 61% · EM ±12.6%Sep 22 — IV 67% · EM ±13.7%Sep 23 — IV 56% · EM ±11.2%Sep 24 — IV 53% · EM ±10.4%Sep 25 — IV 64% · EM ±12.2%Sep 28 — IV 63% · EM ±11.2%Sep 29 — IV 56% · EM ±9.6%Sep 30 — IV 49% · EM ±8.1%Oct 01 — IV 55% · EM ±8.9%Oct 02 — IV 50% · EM ±7.9%Oct 06 — IV 75% · EM ±10.0%Oct 07 — IV 65% · EM ±8.1%Oct 08 — IV 62% · EM ±7.3%

Sector peers

KOD
Kodiak Sciences Inc
$6.2B $85.78-7.7%
CGON
CG Oncology, Inc.
$6.1B $62.54+1.0%
IOVA
Iovance Biotherapeutics, Inc.
$5.9B $14.14-4.8%
RGEN
Repligen Corporation
$8.2B $178.71-0.1%
SRRK
Scholar Rock Holding Corporation
$5.6B $41.96+1.4%
CRSP
CRISPR Therapeutics AG
$5.4B $49.99+0.2%

IMVT earnings FAQ

What is IMVT's expected move for earnings?

Options currently price a move of about ±7.3%, or $2.12 per share either way from $29.10.

How does IMVT stock usually react to earnings?

Across the last 2 reports the average next-day move was ±20.4%, up 2 times and down 0 times.

What is IMVT's implied volatility?

IMVT's at-the-money implied volatility is about 62% based on the latest options snapshot.

View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in